Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 526-529, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-438921
ABSTRACT
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations.Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type.In basic research,EGFR-TKIs combination with chemotherapy drugs show good synergy.But in clinical research,the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS